ArTara Therapeutics, Inc., a clinical-stage company, develops product candidates for patients suffering from rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The company's lead program is TARA-002, a cellular therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. ArTara Therapeutics, Inc. is based in New York, New York.